JAKARTA - Cancer treatment in Indonesia still faces major challenges. Based on the Global Cancer Observatory (GLOBOCAN) 2022, every year there are around 20 million new cases of cancer and almost 9.7 million deaths from cancer worldwide. In Indonesia itself, it is estimated that more than 408 thousand new cases occur with around 242 thousand deaths every year.
In addition to the high number of new cases each year, more than 70% of patients in Indonesia still come to the advanced stage. As a result, the choice of therapy becomes more complex and the chance of treatment success can decrease. This condition shows that early detection and accurate diagnosis from the early stages are important factors to help patients obtain more appropriate therapy and increase the chance of optimal treatment results.
In the midst of these challenges, the development of health technology based on Artificial Intelligence (AI), molecular imaging, and precision oncology is beginning to change the approach to treating cancer. If previously the therapy was determined based on the type of cancer, now doctors can utilize more complete information regarding the characteristics of each patient's disease to determine more targeted therapy.
Answering this need, MRCCC Siloam Semanggi presents four latest generation technologies, namely uMI Panvivo PET/CT, Symbia Pro.specta Q3 SPECT/CT, Spectral CT 7500, and uAngio AVIVA Intelligent Angiography System. The four technologies complement each other in supporting the entire cancer treatment journey, from early detection, diagnosis, determination of disease stage, therapy planning, intervention actions, to evaluation of treatment results.
MRCCC Siloam Semanggi Chief Executive Officer, Tries Nainggolan, said that technology investment is not merely to present the latest devices, but is an effort to ensure that every patient receives increasingly accurate diagnosis and therapy according to their disease condition.
"The journey of cancer patients begins with the right diagnosis. The more accurate information doctors obtain from the diagnosis process, the greater the patient's chance of getting the right therapy. Therefore, we continue to invest in technology that supports more precise clinical decision-making so that every innovation really provides real benefits for patients," said Tries Nainggolan.
uMI Panvivo PET/CT: Helping Find Cancer Earlier
The four latest technologies presented by MRCCC Siloam Semanggi have a complementary role in supporting the precision oncology approach. uMI Panvivo PET/CT is a high-performance molecular imaging modality that utilizes Artificial Intelligence (AI) technology to produce clearer and more detailed image quality. This technology helps doctors detect small lesions, determine the stage of the disease more accurately, and monitor patient response to therapy.
Hospital Director MRCCC Siloam Semanggi, dr. Adityawati Ganggaiswari, M.Biomed, MARS, explained, "The presence of uMI Panvivo PET/CT is an important step in strengthening precision oncology services at MRCCC Siloam Semanggi. In addition to producing high-quality imaging, uMi Panvivo PET/CT supports a more efficient examination process through a shorter scanning time, so that patients can undergo examinations more comfortably."
Symbia Pro.specta SPECT/CT: Evaluation of Organ Function and Disease Spread
Meanwhile, Symbia Pro.specta SPECT/CT combines Single-Photon Emission Computed Tomography (SPECT) and Computed Tomography (CT) technologies to complement nuclear medicine services. This technology allows doctors to provide a more comprehensive overview, evaluate organ function, detect disease spread, and support clinical decision-making.
Spectral CT 7500: Deeper Tissue Analysis
Unlike conventional CT scanners that mainly display anatomical structures, the Spectral CT 7500 uses spectral imaging technology to analyze the characteristics and composition of tissues in a more in-depth manner. This ability allows doctors to distinguish normal tissues and tissues suspected of being cancer with a higher level of accuracy, thus supporting the establishment of diagnosis, determination of disease stage, and preparation of more appropriate therapy strategies according to disease characteristics.
uAngio AVIVA Intelligent Angiography System: More Accurate and Safe Minimal Invasive Actions
The presence of intervention technology is also becoming increasingly important because cancer patients have a higher risk of cardiovascular disease. A Johns Hopkins University study (2020) showed that cancer survivors have a 42% higher risk of cardiovascular disease and a 59% higher risk of heart failure than the population without a history of cancer.
dr. Adityawati Ganggaiswari, M.Biomed, MARS, added that modern cancer services not only focus on cancer treatment, but also on managing co-morbid conditions that can affect the success of therapy.
"To ensure that patients receive comprehensive treatment, MRCCC Siloam Semanggi also strengthens interventional services through uAngio AVIVA Intelligent Angiography System. This technology supports various procedures more precisely so that patients can receive safer and comprehensive treatment," he said.
uAngio AVIVA Intelligent Angiography System supports various minimally invasive procedures, both for the treatment of heart disease and procedures that support cancer therapy, such as vascular access placement, imaging-based biopsy, and embolization. With AI support, this system improves the accuracy of visualization during procedures, helps improve the efficiency of the procedure, and helps reduce radiation exposure for patients and medical personnel.
Furthermore, the Chief Executive Officer of MRCCC Siloam Semanggi, Tries Nainggolan, emphasized that technology does not replace the role of medical personnel, but rather strengthens the ability of doctors to make more appropriate clinical decisions.
"Technology is a tool for doctors to obtain more complete and accurate information. When innovation is combined with health worker competence and multidisciplinary collaboration, patients have a greater chance of obtaining the right diagnosis and more optimal treatment," he concluded.
The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)
